Amundi Asset Management US’s Amicus Therapeutics FOLD Stock Holding History

Amundi Asset Management US’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$173K	Hold	17,500	–	–	﹤0.01%	1473
2020 Q4	$404K	Hold	17,500	–	–	﹤0.01%	1326
2020 Q3	$247K	Hold	17,500	–	–	﹤0.01%	1362
2020 Q2	$264K	Hold	17,500	–	–	﹤0.01%	1340
2020 Q1	$162K	Hold	17,500	–	–	﹤0.01%	1366
2019 Q4	$170K	Hold	17,500	–	–	﹤0.01%	1503
2019 Q3	$140K	Buy	17,500 +3,800	+28%	+$41.2K	﹤0.01%	1527
2019 Q2	$171K	Hold	13,700	–	–	﹤0.01%	1498
2019 Q1	$186K	Hold	13,700	–	–	﹤0.01%	1450
2018 Q4	$131K	Sell	13,700 -9,200	-40%	-$101K	﹤0.01%	1461
2018 Q3	$277K	Buy	+22,900	New	+$320K	﹤0.01%	1430

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amundi Asset Management US's FOLD Position: Q1 2021 in Review

Amundi Asset Management US held its Amicus Therapeutics (FOLD) position steady in Q1 2021 at 17,500 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #1473.

Amundi Asset Management US first reported a position in FOLD in Q3 2018 and has held it in 11 quarters since. The position peaked at $404K in Q4 2020. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

Amundi Asset Management US held 17,500 shares of Amicus Therapeutics worth $173K as of Q1 2021.
Amundi Asset Management US left its Amicus Therapeutics share count unchanged in Q1 2021.
Amicus Therapeutics made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1473 holding.
Amundi Asset Management US first reported a position in Amicus Therapeutics in Q3 2018 and has held it in 11 quarters since.
Amundi Asset Management US's Amicus Therapeutics position peaked at $404K in Q4 2020.
259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.